ECSP13012667A - Compuestos de triazolopiridina - Google Patents
Compuestos de triazolopiridinaInfo
- Publication number
- ECSP13012667A ECSP13012667A ECSP13012667A ECSP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- triazolopiridine
- medicines
- formula
- well
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 abstract 1
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a compuestos de triazolopiridina de la fórmula (I) (I)en la que R1, R2, R3 y R4 tienen los significados definidos en la descripción y en las reivindicaciones, así como a las sales fisiológicamente aceptables de los mismos. Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012667A true ECSP13012667A (es) | 2013-08-30 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012667 ECSP13012667A (es) | 2010-12-07 | 2013-06-06 | Compuestos de triazolopiridina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (es) |
| EP (1) | EP2649070B1 (es) |
| JP (1) | JP5932828B2 (es) |
| KR (1) | KR20130128426A (es) |
| CN (1) | CN103237803B (es) |
| AR (1) | AR084152A1 (es) |
| AU (1) | AU2011340685A1 (es) |
| BR (1) | BR112013013912A2 (es) |
| CA (1) | CA2816829C (es) |
| CL (1) | CL2013001591A1 (es) |
| CO (1) | CO6741154A2 (es) |
| CR (1) | CR20130239A (es) |
| CY (1) | CY1115863T1 (es) |
| DK (1) | DK2649070T3 (es) |
| EA (1) | EA022607B1 (es) |
| EC (1) | ECSP13012667A (es) |
| ES (1) | ES2520647T3 (es) |
| HR (1) | HRP20141200T1 (es) |
| IL (1) | IL225969A0 (es) |
| MA (1) | MA35086B1 (es) |
| MX (1) | MX2013006054A (es) |
| PE (1) | PE20140226A1 (es) |
| PH (1) | PH12013500942A1 (es) |
| PL (1) | PL2649070T3 (es) |
| PT (1) | PT2649070E (es) |
| RS (1) | RS53677B1 (es) |
| SG (1) | SG190305A1 (es) |
| SI (1) | SI2649070T1 (es) |
| UA (1) | UA109037C2 (es) |
| WO (1) | WO2012076430A1 (es) |
| ZA (1) | ZA201303811B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2757882B1 (en) | 2011-09-22 | 2020-11-04 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| CA2858778A1 (en) | 2012-02-09 | 2013-08-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives |
| HK1210610A1 (en) * | 2013-01-31 | 2016-04-29 | 霍夫曼-拉罗奇有限公司 | Radiolabeled compounds |
| NZ708593A (en) | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| MY169128A (en) * | 2013-04-30 | 2019-02-18 | Hoffmann La Roche | Pd-catalyzed coupling of pyrazole amides |
| WO2014192936A1 (ja) * | 2013-05-31 | 2014-12-04 | 日産化学工業株式会社 | 複素環アミド化合物 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| JP6568855B2 (ja) * | 2014-07-30 | 2019-08-28 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
| CN107074844A (zh) * | 2014-07-30 | 2017-08-18 | 持田制药株式会社 | 吡唑衍生物的制造方法 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN116137811B (zh) * | 2020-06-05 | 2026-01-09 | 诺埃玛制药公司 | 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| WO2022162193A1 (en) | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
| WO2026068583A1 (en) | 2024-09-25 | 2026-04-02 | Noema Pharma Ag | Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 PH PH1/2013/500942A patent/PH12013500942A1/en unknown
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Ceased
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 CA CA2816829A patent/CA2816829C/en active Active
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/en active Active
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 RS RS20140574A patent/RS53677B1/sr unknown
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/en not_active Ceased
- 2011-12-05 HR HRP20141200AT patent/HRP20141200T1/hr unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012667A (es) | Compuestos de triazolopiridina | |
| ECSP12012174A (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| ECSP13013074A (es) | Nuevos derivados de piridina | |
| ECSP11011411A (es) | Derivados de prolina como inhibidores de catepsina | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| DOP2011000382A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| CO6620065A2 (es) | Compuestos heteroarilo nitrogenados | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| CR20150277A (es) | Piridina-2-amidas utiles como agonistas cb2 | |
| CO6541606A2 (es) | Espiroindolinona- pirrolidinas | |
| MX2019009100A (es) | Nuevos derivados de triazolo[4,5-d]pirimidina. | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| UA108711C2 (uk) | Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| CR20140481A (es) | Compuestos triazolo como inhibidores de pde10 | |
| CR20150210A (es) | Nuevos derivados de pirazina como agonistas receptores de cb2 | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| CR20150511A (es) | Nuevos derivados de purina | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
| UY31000A1 (es) | Oxoisoxazoles como inhibidores de lipasas y fosfolipasas | |
| HN2009001330A (es) | Compuestos novedosos activos como antagonistas de receptore muscarinico | |
| BR112014019220A8 (pt) | Novos derivados de pirrolidina |